Latest From MorphoSys AG
The Japanese biotech agreed a multi-year, multi-target research collaboration and license deal with Takeda to discover and develop medicines that modulate GPCR targets, initially in GI.
Skyhawk continues its recent spate of deal-making, using its SkyStar platform in a deal with Genentech, which also is looking into neurology with Convelo. AbbVie buys STING specialist Mavupharma, while Recordati pays Novartis $390m for Cushing’s products.
Vivoryon CEO explains how QPCTL-targeting small molecule technology will be tested for combination with MorphoSys’s tafasitamab to enhance cancer-killing efficacy.
GlaxoSmithKline is exploring a potential new way of tackling rheumatoid arthritis in just-started Phase III studies which could shake up a disease sector that is already attracting interest from other big pharma companies.
Drug Discovery Tools
- Molecular Diversity
- Drug Discovery Tools
- In Vitro Diagnostics
- Research, Analytical Equipment & Supplies
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Immune Disorders
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Respiratory, Pulmonary
- Western Europe
- Parent & Subsidiaries
- MorphoSys AG
- Senior Management
Simon E Moroney, PhD, CEO
Jens Holstein, CFO
Malte Peters, MD, Chief Dev. Officer
Markus Enzelberger , PhD, CSO
- Contact Info
Phone: (49) 89 899 27 0
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.